What happens in the world of Facebook cannot be ignored in pharma marketing. It increasingly lives in a world of data that is highly sensitive and must be managed well.
The Food and Drug Administration regulates more than a third of the U.S. economy. And its new commissioner, Scott Gottlieb, is trying to shake up how it does so.
In his first press conference as president-elect, Donald Trump insisted pharma was "getting away with murder" due to expensive drug prices.
As researchers and analysts, we interact with a wide array of market research pros in the health and wellness space.
It turns out the real goal is going after Washington's favorite whipping boy — high drug prices.
As professional communicators, it's about time we figured out how we can initiate those conversations, says a creative director at RTO+P.
A study by Cohn & Wolfe cited that 63% of consumers would choose a company they believe to be authentic over its competitors.
Technology like this could expand further to form better collaborations between pharma, payers and organized providers.
How should marketers demonstrate the value of non-personal promotion?
How should marketers position this new type of cancer therapy?
Every agency in the biz claims to have a "unique" culture and one that fuels a great deal of its success.
Management turnover has brought the opportunity to keep up the pressure.
How can marketers do more with less, or otherwise convince skeptical executives that more resources will lead to long-term change?
There is a misperception in the U.S. that we have "conquered" heart disease and stroke, but the evidence shows that this is far from true.
HYC Health's Rich Angelini examines campaigns from Pfizer, Allergan, and Purell.
Merck CEO Kenneth Frazier's exit from a presidential manufacturing council may go down as one of the most principled stands by the CEO of a major U.S. company, let alone a drugmaker.
The coming digital revolution will change a lot of things, but I guarantee this: It won't replace the importance of the patient-physician relationship.
How can marketers ensure that patients and physicians aren't overwhelmed by these tactics?
The Lions Health awards were meant to recognize standout communications in the uniquely specialized pharma industry. Staying true to that mission has proved challenging.
Beset by high prices and scientific complexity, how can marketers best communicate the value of specialty drugs?
How can agencies best entice clients to incorporate behavioral science into their marketing programs?
How can marketers incorporate patient feedback into their marketing strategies without expensive and time-consuming studies?
Nothing is more personal than an individual's health; the technology that will prove most effective will be solutions that are personal.
With rep access to physicians on the decline, what are the most effective non-personal promotional tactics marketers can use to connect with prescribers?
We should make off-label research publicly available in a non-promotional format to both healthcare professionals and patients.
Data analytics, relationship building, and improved patient support are the keys to differentiating your rare-disease drug brands, according to these four marketers.
Does virtual reality represent a new way for marketers to create immersive experiences — or is this just the industry's latest shiny object?
Pharma must be thoughtful in its approach and demonstrate value to be part of the EHR conversation.
It's been called "America's other drug problem."
Pharma marketing has long been deemed slow to adapt. Last weekend's Lions Health festival offered a glimpse of healthcare as a first mover.